Gastric cancer in the era of molecularly targeted agents: Current drug development strategies

Journal of Cancer Research and Clinical Oncology

Volumn 135, Issue 7, 2009, Pages 855-866

  Arkenau, Hendrik Tobias ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Gastric cancer; Gastroesophageal cancer; GEJ; Molecularly targeted agents

Indexed keywords

ANTINEOPLASTIC AGENT; BRIVANIB; CETUXIMAB; CP 751871; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; LAPATINIB; MATUZUMAB; OSI 906; OXALIPLATIN; PANITUMUMAB; SCATTER FACTOR RECEPTOR; SEMAXANIB; SOMATOMEDIN; SOMATOMEDIN RECEPTOR; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VADATENIB; VASCULOTROPIN; CELL SURFACE RECEPTOR; TUMOR MARKER;

ADVANCED CANCER; CANCER SCREENING; CELL CYCLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; INJECTION SITE REACTION; METASTASIS; PRIORITY JOURNAL; REVIEW; SKIN TOXICITY; STOMACH CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG EFFECT; DRUG SCREENING; GENETIC EPIGENESIS; GENETICS; METHODOLOGY; STOMACH TUMOR;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; DRUG SCREENING ASSAYS, ANTITUMOR; EPIGENESIS, GENETIC; HUMANS; RECEPTORS, CELL SURFACE; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 66949170649     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-009-0583-7     Document Type: Review

References (96)

1. H Amemiya K Kono J Itakura 2002 C-Met expression in gastric cancer with liver metastasis Oncology 63 3 286 296 10.1159/000065477
2. G Attard PC Fong R Molife 2006 Phase I trial involving the pharmacodynamic (PD) study of circulating tumour cells, of CP-751, 871 (C), a monoclonal antibody against the insulin-like growth factor 1 receptor (IGF-1R), with docetaxel (D) in patients (p) with advanced cancer J Clin Oncol 24 3023
3. SH Bae HM Ryoo MK Kim 2008 Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines Oncol Rep 19 4 1027 1032 (Pubitemid 351802676)
4. Y Bang Y Kang W Kang 2007 Sunitinib as second-line treatment for advanced gastric cancer: preliminary results from a phase II study J Clin Oncol 25 4603 10.1200/JCO.2007.10.8688
5. Y Bang H Chung A Sawaki 2008 HER2-positivity rates in advanced gastric cancer (GC): results from a large international phase III trial J Clin Oncol 26 4526
6. JE Bolden MJ Peart RW Johnston 2006 Anticancer activities of histone deacetylase inhibitors Nat Rev Drug Discov 5 9 769 784 10.1038/nrd2133
7. SR Bramhall MT Hallissey J Whiting 2002 Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial Br J Cancer 86 12 1864 1870 10.1038/sj.bjc.6600310
8. P Carmeliet 2003 Angiogenesis in health and disease Nat Med 9 653 660 10.1038/nm0603-653
9. G Carpenter S Cohen 1990 Epidermal growth factor J Biol Chem 265 7709 7712 (Pubitemid 20158927)
10. B Cauwe PE Van den Steen G Opdenakker 2007 The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases Crit Rev Biochem Mol Biol 42 3 113 185 10.1080/ 10409230701340019
11. Cejka D, Preusser M, Woehrer A et al. (2008) Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo. Cancer Biol Ther 7(9) (epub ahead of print)
12. Cheema HS, Motwani MV et al. (2004) Suberoylanilide Hydroxamic Acid (SAHA), a histone deacetylase (HDAC) inhibitor, induces a unique mitotic effect and potentiates flavopiridol (F) induced apoptosis. Proc Am Assoc Cancer Res 45: 2443
13. Cohenuram MK, Lacy J (2008) FOLFOX6 and bevacizumab (FOLFOX6/B) for metastatic esophageal (E), gastroesophageal (GE), and gastric (G) adenocarcinoma: a single institution's initial clinical experience. Proc GI ASCO: 74
14. H Cortés-Funes F Rivera I Alés 2007 Phase II of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with HER2/neu overexpression/amplification J Clin Oncol 25 4613
15. AA Dar A Zaika MB Piazuela 2008 Frequent overexpression of aurora kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions Cancer 112 8 1688 1698 10.1002/cncr.23371
16. M de Mingo A Morán A Sánchez-Pernaute 2007 Expression of MMP-9 and TIMP-1 as prognostic markers in gastric carcinoma Hepatogastroenterology 54 73 315 319 (Pubitemid 46511697)
17. T Dragovich S McCoy CM Fenoglio-Preiser 2006 Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127 J Clin Oncol 24 30 4922 4927 10.1200/JCO.2006.07.1316
18. FA Eskens CH Mom AS Planting 2008 A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours Br J Cancer 98 1 80 85 10.1038/sj.bjc. 6604108
19. T Fujita H Doihara K Washio 2007 Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells Anticancer Drugs 18 6 677 686 10.1097/CAD.0b013e32808bf9d8
20. SJ Gong CJ Jin SY Rha 2004 Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines Cancer Lett 214 2 215 224 10.1016/j.canlet.2004.04.029
21. A Grimber P Cohen 2000 Role of insulin-like growth factor and their binding proteins in growth control and carcinogenesis J Cell Physiol 183 1 9 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J
22. P Haluska H Shaw GN Batzel 2007 Phase I dose escalation study of the anti-IGF-1R monoclonal antibody CP-751, 871 in patients with refractory solid tumors J Clin Oncol 25 3586
23. Hammad N, Philip PA, Shields AF et al. (2008) A phase II study of bevacizumab, docetaxel, and oxaliplatin in gastric and gastroesophageal junction (GEJ) cancer. Proc GI ASCO: 30
24. Z Han K Wu H Shen 2008 Akt1/protein kinase B alpha is involved in gastric cancer progression and cell proliferation Dig Dis Sci 53 7 1801 1810 10.1007/s10620-007-9824-2
25. SW Han DY Oh SA Im 2009 Phase II study and biomarker analysis of cetuximab in combination with modified FOLFOX6 in advanced gastric cancer Br J Cancer 100 2 298 304 10.1038/sj.bjc.6604861
26. Y Hattori H Itoh S Uchino 1996 Immunohistochemical detection of K-sam protein in stomach cancer Clin Cancer Res 2 8 1373 1381 (Pubitemid 26299437)
27. Hecht JR, Urba SG, Koehler M et al. (2008) Lapatinib monotherapy in recurrent upper gastrointestinal malignancy: phase II efficacy and biomarker analyses. Proc GI ASCO: 43
28. JR Hecht E Mitchell T Chidiac 2009 A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer J Clin Oncol 27 5 672 680 10.1200/JCO.2008.19.8135
29. Y Hinoda S Sasaki T Ishida 2004 Monoclonal antibodies as effective therapeutic agents for solid tumors Cancer Sci 96 443 446
30. A Hirata S Ogawa T Kometani 2002 ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase Cancer Res 62 9 2554 2560 (Pubitemid 34462734)
31. T Inoue H Kataoka K Goto 2004 Activation of c-Met (hepatocyte growth factor receptor) in human gastric cancer tissue Cancer Sci 95 10 803 808 10.1111/j.1349-7006.2004.tb02185.x
32. S Iqbal B Goldman HJ Lenz 2007 S0413: a phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients (pts) with advanced or metastatic gastric cancer J Clin Oncol 25 4621
33. J Iwamoto Y Mizokami K Takahashi 2008 The effects of cyclooxygenase2- prostaglandinE2 pathway on Helicobacter pylori-induced urokinase-type plasminogen activator system in the gastric cancer cells Helicobacter 13 3 174 182 10.1111/j.1523-5378.2008.00597.x
34. YJ Jang YS Kim WH Kim 2006 Oncogenic effect of Polo-like kinase 1 expression in human gastric carcinomas Int J Cancer 29 3 589 594
35. Jhawer MP, Ilson D, Robinson E et al. (2008) Interim results of a phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma. Proc GI ASCO: 109
36. MP Jhawer HL Kindler ZA Wainberg 2008 Preliminary activity of XL880, a dual MET/VEGFR2 inhibitor, in MET amplified poorly differentiated gastric cancer (PDGC): interim results of a multicenter phase II study J Clin Oncol 26 4572 10.1200/JCO.2007.15.5655
37. HE Jones JMW Gee IR Hutcheson 2006 Growth factor receptor interplay and resistance in cancer Endocr Relat Cancer 13 Suppl 1 S45 S51 10.1677/erc.1.01275
38. K Kamada Y Yamada T Hirao 2004 Amplification/overexpression of Aurora-A in human gastric carcinoma: potential role in differentiated type gastric carcinogenesis Oncol Rep 12 3 593 599
39. AJ Karayiannakis KN Syrigos A Polychronidis 2002 Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery Ann Surg 236 1 37 42 10.1097/00000658-200207000-00007
40. Kim JW, Kim HP, Im SA et al. (2008) The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett (e-pub ahead of print)
41. T Kuwano S Nakao H Yamamoto 2004 Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis FASEB J 18 2 300 310 10.1096/fj.03-0473com
42. SA Lang D Klein C Moser 2007 Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo Mol Cancer Ther 6 3 1123 1132 10.1158/1535-7163.MCT-06-0628
43. SA Lang A Gaumann GE Koehl 2007 Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model Int J Cancer 120 8 1803 1810 10.1002/ijc.22442
44. AJ Lax W Thomas 2002 How bacteria could cause cancer: one step at a time Trends Microbiol 10 6 293 299 10.1016/S0966-842X(02)02360-0
45. F Lordick S Lorenzen S Hegewisch-Becker 2007 Cetuximab plus weekly oxaliplatin/5FU/FA (FUFOX) in 1st line metastatic gastric cancer. Final results from a multicenter phase II study of the AIO upper GI study group J Clin Oncol 26 4526
46. T Macarulla FJ Ramos J Tabernero 2008 Aurora kinase family: a new target for anticancer drug Recent Patents Anticancer Drug Discov 3 2 114 122
47. A Mani EP Gelmann 2005 The Ubiquitin-Proteasome pathway and its role in cancer J Clin Oncol 23 21 4776 4789 10.1200/JCO.2005.05.081
48. JR Mann MG Backlund RN DuBois 2005 Mechanisms of disease: inflammatory mediators and cancer prevention Nat Clin Pract Oncol 2 4 202 210 10.1038/ncponc0140
49. PA Marks X Jiang 2005 Histone deacetylase inhibitors in programmed cell death and cancer therapy Cell Cycle 4 4 549 551 (Pubitemid 41359778)
50. T Marumoto T Hirota T Morisaki 2002 Roles of aurora-A kinase in mitotic entry and G2 checkpoint in mammalian cells Genes Cells 7 1173 1182 10.1046/j.1365-2443.2002.00592.x
51. J Matsubara Y Yamada Y Hirashima 2008 Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer Clin Cancer Res 14 10 3022 3029 10.1158/1078-0432.CCR-07-1898
52. G Maulik A Shrikhande T Kijima 2002 Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition Cytokine Growth Factor Rev 13 1 41 59 10.1016/S1359-6101(01)00029-6
53. MF McCarty J Wey O Stoeltzing 2004 ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer Mol Cancer Ther 3 9 1041 1048 (Pubitemid 39295001)
54. A Miremadi MZ Oestergaard PD Pharoah 2007 Cancer genetics of epigenetic genes Hum Mol Genet 16 1 R28 R49 10.1093/hmg/ddm021
55. Moehler M, Hartmann JT, Lordick F et al. (2009) Sunitinib in patients with chemorefractory metastatic gastric cancer: preliminary results of an open-label, prospective non-randomised multicentre AIO Phase II trial. Proc GI ASCO: 61
56. D Morgensztern HL McLeod 2005 PI3K/Akt/mTOR pathway as a target for cancer therapy Anticancer Drugs 16 8 797 803 10.1097/01.cad.0000173476.67239.3b
57. RJ Motzer TE Hutson P Tomczak 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2 115 124 10.1056/NEJMoa065044
58. K Muro N Boku Y Yamada 2008 Multicenter phase II study of RAD001 for previously treated metastatic gastric cancer (MGC): preliminary results J Clin Oncol 26 4541
59. M Nakajima H Sawada Y Yamada 2000 The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas Cancer 85 1894 1902
60. K Nakamura M Yashiro T Matsuoka 2006 A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer Gastroenterology 131 5 1530 1541 10.1053/j.gastro.2006.08.030
61. Ocean AJ, Schnoll-Sussman F, Chen X et al. (2007) Phase II study of PS-341 (VELCADE, bortezomib) with or without irinotecan in patients (pts) with advanced gastric adenocarcinomas (AGA). Proc GI ASCO: 45
62. E Oki H Baba E Tokunaga 2005 Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer Int J Cancer 117 3 376 380 10.1002/ijc.21170
63. JH Park Y Jung TY Kim 2004 Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation Clin Cancer Res 10 15 5271 5281 10.1158/1078-0432.CCR-03-0709
64. C Pinto F Di Fabio S Siena 2007 Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study) Ann Oncol 18 3 510 517 10.1093/annonc/mdl459
65. Pinto C, Di Fabio F, Barone C et al. (2008) Phase II study of cetuximab in combination with cisplatin/docetaxel as first-line treatment in patients with unresectable/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (DOCETUX Study): preliminary results. Proc GI ASCO: 34
66. LG Presta H Chen SJ O'Connor 1997 Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders Cancer Res 57 4593 4599 (Pubitemid 27441066)
67. Rao S, Starling N, Cunningham D et al. (2008) Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. Br J Cancer (epub ahead of print)
68. F Rojo J Tabernero J Albanell 2006 Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma J Clin Oncol 24 26 4309 4316 10.1200/JCO.2005.04.2424
69. LB Saltz NJ Meropol PJ Loehrer 2004 Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J Clin Oncol 22 1201 1208 10.1200/JCO.2004.10.182
70. LB Saltz HJ Lenz HL Kindler 2007 Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 Study J Clin Oncol 25 4557 4561 10.1200/JCO.2007.12.0949
71. GK Schwartz D Ilson L Saltz 2001 Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma J Clin Oncol 19 7 1985 1992 (Pubitemid 32702543)
72. AM Senderowicz 2000 Small molecule modulators of cyclin-dependent kinases for cancer therapy Oncogene 19 56 6600 6606 10.1038/sj.onc.1204085
73. MA Shah RK Ramanathan DH Ilson 2006 Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma J Clin Oncol 24 33 5201 5206 10.1200/JCO.2006.08.0887
74. J Song JH Noh JH Lee 2005 Increased expression of histone deacetylase 2 is found in human gastric cancer APMIS 113 4 264 268 10.1111/j.1600-0463.2005. apm-04.x
75. Stein A, Al-Batran SE, Arnold D et al. (2007) Cetuximab with irinotecan as salvage therapy in heavily pretreated patients with metastatic gastric cancer. Proc GI ASCO: 47
76. W Sun ME Powell P O'Dwyer 2008 A phase II study: combination of sorafenib with docetaxel and cisplatin in the treatment of metastatic or advanced unresectable gastric and gastroesophageal junction (GEJ) adenocarcinoma (ECOG 5203) J Clin Oncol 26 4535
77. E Tahara 2004 Genetic pathways of two types of gastric cancer IARC Sci Publ 157 327 349
78. N Takai R Hamanaka J Yoshimatsu 2005 Polo-like kinases (Plks) and cancer Oncogene 24 2 287 291 10.1038/sj.onc.1208272
79. M Tanner M Hollmen TT Junttila 2005 Amplification of HER-2 in gastric carcinoma: association with topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab Ann Oncol 16 273 278 10.1093/annonc/mdi064
80. NC Tebbutt T Sourjina AH Strickland 2008 ATTAX2: docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophago-gastric cancer-final results of a multicentre phase II trial by the AGITG J Clin Oncol 26 15554
81. JP Thomas KD Tutsch JF Cleary 2002 Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol Cancer Chemother Pharmacol 50 6 465 472 10.1007/s00280-002-0527-2
82. GM Tierney NR Griffin RC Stuart 1999 A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer Eur J Cancer 35 4 563 568 10.1016/S0959-8049(99)00007-6
83. Tol J, Koopman M, Cats A et al. (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360(6):563-572
84. G Tortora F Ciardiello G Gasparini 2008 Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications Nat Clin Pract Oncol 5 9 521 530 10.1038/ncponc1161
85. S Tsutsumi L Neckers 2007 Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis Cancer Sci 98 10 1536 1539 10.1111/j.1349-7006.2007.00561.x
86. E Van Cutsem M Peeters S Siena 2007 Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer J Clin Oncol 25 13 1658 1664 10.1200/JCO.2006.08.1620
87. N Wada Y Otani T Kubota 2003 Reduced angiogenesis in peritoneal dissemination of gastric cancer through gelatinase inhibition Clin Exp Metastasis 20 5 431 435 10.1023/A:1025453500148
88. HK Wang 2001 Flavopiridol. National Cancer Institute Curr Opin Invest Drugs 2 8 1149 1155
89. WH Wang JQ Huang GF Zheng 2003 Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis J Natl Cancer Inst 95 23 1784 1791 (Pubitemid 38008901)
90. W Weichert A Ullrich M Schmidt 2006 Expression patterns of polo-like kinase 1 in human gastric cancer Cancer Sci 97 4 271 276 10.1111/j.1349-7006. 2006.00170.x
91. W Weichert A Röske V Gekeler 2008 Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis Lancet Oncol 9 2 139 148 10.1016/S1470-2045(08)70004-4
92. E Woell R Greil W Eisterer 2008 Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer: first results of a multicenter phase II trial (AGMT Gastric-2) J Clin Oncol 26 15587
93. TA Yap D Harris J Barriuso 2008 Phase I trial to determine the dose range for the c-Met inhibitor ARQ 197 that inhibits c-Met and FAK phosphorylation, when administered by an oral twice-a-day schedule J Clin Oncol 26 3584
94. XM Zou YL Li H Wang 2008 Gastric cancer cell lines induced by trichostatin A World J Gastroenterol 14 30 4810 4815 10.3748/wjg.14.4810
95. S Zucker J Cao WT Chen 2000 Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment Oncogene 19 56 6642 6650 10.1038/sj.onc.1204097
96. DS Zuo J Dai AH Bo 2003 Significance of expression of heat shock protein90alpha in human gastric cancer World J Gastroenterol 9 11 2616 2618 (Pubitemid 37461282)